Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain waves and meditation show promise for Schizophrenia's 'Negative' symptoms

NCT ID NCT07437365

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether guided meditation combined with binaural beats (special sound frequencies) could help reduce negative symptoms of schizophrenia, like low motivation and social withdrawal. Ninety inpatients were assigned to meditation alone or meditation with either alpha- or theta-frequency sounds. Results showed that those who received meditation with binaural beats improved more, with the theta-frequency group showing the greatest benefit. While not all differences were statistically significant, this simple, low-cost approach may offer a new way to help manage persistent symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
guided meditation with binaural beats (alpha or theta frequency)
What this could lead to
If confirmed, this low-cost, non-drug approach could offer a new way to ease persistent negative symptoms like low motivation and social withdrawal in schizophrenia.
What could go wrong
This was a small, single-site study with 90 participants. Not all improvements were statistically significant, and larger studies are needed to confirm the findings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

90 people

The number who actually took part.

Started

Aug 2025

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Hospitalized patients at the psychiatrics hospital of the cross * Aged between 18 and 65 years * Diagnosed with schizophrenia according to the diagnostic and statistical manual of mental disorders, fifth edition (DSM-5) * Clinically stable, receiving a consistent dose of antipsychotic medication for at least 3 months before recruitment Exclusion Criteria: * Acute psychiatric symptoms requiring immediate intervention or hospitalization * Current diagnosis of substance use disorder * Documented history of non-compliance with medical treatment * Hearing impairments that could affect accurate perception of auditory stimuli such as binaural beats

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Schizophenia disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Psychiatric Hospital of the Cross

    Beirut, Lebanon

More trials for these conditions

Other studies related to the condition(s) this trial covers.